TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania. Show more

Location: 1 Great Valley Parkway, Malvern, PA, 19355, United States | Website: https://www.telabio.com | Industry: Medical Devices | Sector: Healthcare


Market Cap

79.11M

52 Wk Range

$0.86 - $5.17

Previous Close

$2.07

Open

$2.11

Volume

79,538

Day Range

$2.00 - $2.17

Enterprise Value

77.03M

Cash

42.83M

Avg Qtr Burn

-9.234M

Insider Ownership

8.31%

Institutional Own.

78.19%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date